Lee Kalowski - Aug 23, 2021 Form 4 Insider Report for BICYCLE THERAPEUTICS plc (BCYC)

Role
President and CFO
Signature
/s/ Lee Kalowski
Stock symbol
BCYC
Transactions as of
Aug 23, 2021
Transactions value $
-$235,650
Form type
4
Date filed
8/25/2021, 05:45 PM
Previous filing
Jul 30, 2021
Next filing
Aug 27, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BCYC Ordinary Shares Options Exercise $12K +7.5K $1.60* 7.5K Aug 23, 2021 Direct F1, F2
transaction BCYC Ordinary Shares Sale -$248K -7.5K -100% $33.02 0 Aug 23, 2021 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BCYC Stock Option (Right to Buy) Options Exercise $0 -7.5K -11.15% $0.00 59.8K Aug 23, 2021 Ordinary Shares 7.5K $1.60 Direct F1, F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares exercised and sold pursuant to a Rule 10b5-1 trading plan.
F2 This exercise price is in US Dollars and reflects the conversion of GBP to USD at an exchange rate of $1.366815 to GBP 1.00 as of August 23, 2021.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.056 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 20% of the shares subject to the option vested on July 24, 2018, 60% of the shares subject to the option will vest each month thereafter in 36 equal monthly installments, and the remaining 20% of the shares subject to the option will vest on the earlier of (i) the fourth anniversary of the grant date and (ii) the date on which the Issuer's board of directors determines that the Issuer has satisfied certain performance vesting milestones, in all cases provided that the Reporting Person remains continuously employed with us through each applicable vesting date.